查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138386

全球套细胞淋巴瘤市场-2022-2029

Global Mantle Cell Lymphoma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

主要驱动因素是套细胞淋巴瘤的患病率不断提高，以及由于医疗保健行业的研发活动增加而不断增长的产品线。

正在进行的研发活动预计将推动市场增长。

一个有前途的套细胞淋巴瘤管道将在预测期内推动市场增长。例如，阿斯利康 (AstraZeneca) 正在讚助一项针对用这种新型药物治疗的套细胞淋巴瘤患者的前瞻性疾病登记，预计将于 2024 年 3 月 20 日完成。由首尔国立大学医院赞助的一项 2 期研究，旨在评估硼替佐米、阿糖胞甘和地塞米鬆对復发或难治性套细胞淋巴瘤患者的疗效，计划于 2025 年 6 月开始，復发并由 Precog 赞助 - 一项 I/II 期试验ixazomib和ibrutinib治疗难治性套细胞淋巴瘤等。此外，与武田联合开展的ixazomib维持治疗新诊断套细胞淋巴瘤患者的多中心II期研究预计将于2024年12月完成（Kosin大学福音医院，武田製药赞助，预计上市时间：12月2022）计划于2022年完成。

高昂的开发成本和副作用的出现预计将阻碍全球套细胞淋巴瘤市场的增长。

然而，贫血、中性粒细胞减少和腹泻等严重的药物副作用正在抑制市场增长。

行业分析。

全球套细胞淋巴瘤市场报告根据波特五力、创新、新产品发布、定价分析和管道分析等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

COVID-19 对全球套细胞淋巴瘤市场产生了重大影响。由于 COVID-19 遏制协议，许多市场参与者的供应链被打乱，导致原材料短缺并扰乱供应链。此外，由于社会化规定，定期健康检查困难，大部分□□套细胞淋巴瘤患者未被发现，这对大流行期间全球套细胞淋巴瘤市场的增长产生了负面影响。

套细胞淋巴瘤全球市场报告将提供对大约 40 多个市场数据表、45 多个图表和 200 多页（大约）的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 研发
      • 癌症患者增加
    • 限制因素
      • 开发成本高
      • 副作用
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 靶向治疗
  • 化疗
  • 放射治疗
  • 其他

第 8 章给药途径

  • 口语
  • 注入

第 9 章，最终用户

  • 医院和诊所
  • 癌症研究中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • Kite Pharma, Inc.（Gilead Sciences, Inc.）
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • F. Hoffman La Roche Ltd
  • Abbvie, Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Amgen, Inc.
  • Takeda Pharmaceutical Co. Ltd
  • AstraZeneca Plc
  • Johnson and Johnson

第13章 DataM

简介目录
Product Code: DMPH2172

Market Overview

Mantle Cell Lymphoma Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7% during the forecast period (2022-2029).

Mantle cell lymphoma (MCL) is a rare type of blood cancer due to the excessive growth of lymphocytes. Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas, which occur due to the formation of tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver.

Market Dynamics

The major driving forces are the growing prevalence of mantle cell lymphoma and increasing research & development activities in the healthcare sector resulting in a robust product pipeline.

The presence of ongoing research and development activities is expected to drive market growth.

The promising mantle cell lymphoma pipeline will drive market growth over the forecast period. For instance, AstraZeneca has sponsored a prospective disease registry of patients with mantle cell lymphoma treated with novel agents and is anticipated to be completed on March 20, 2024; a Phase 2 trial to assess the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma, sponsored by Seoul National University Hospital and is anticipated to be launched in June 2025, a Phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma sponsored by PrECOG, LLC. In collaboration with Takeda and anticipated to be completed in December 2024 and a Multicenter Phase II study of ixazomib maintenance in patients with newly diagnosed mantle cell lymphoma, Kosin University Gospel Hospital, in collaboration with Takeda sponsored and expected launch is in December 2022.

The high development cost and the onset of side effects are expected to hinder global mantle cell lymphoma market growth.

However, serious side effects of drugs like anemia, neutropenia, and diarrhea are restraining market growth.

Industry analysis.

The global mantle cell lymphoma market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global mantle cell lymphoma market. Because of the COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials, which disturbed the supply and demand chain. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.

Segment Analysis

The targeted therapy segment is assumed to command the Mantle Cell Lymphoma market throughout the forecast period (2022-2029).

The targeted therapy segment is expected to grow rapidly over the forecast period (2022-2029). Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent's ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD. For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.

Geographical Analysis

The North American region holds the largest market share of the global Mantle Cell Lymphoma market.

North America dominated the global mantle cell lymphoma market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of key market players in North America and their hold over the global market with increasing research and development activities. For instance, on July 24, 2020, a U.S.-based company, Kite, A Gilead Company. LLS secured the approval for its brexucabtagene autoleucel (formerly KTE-X19, now branded as Tecartus) as the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with MCL. Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market. According to the U.S. Census Bureau estimation, over 54 million adults aged 65 and older in 2020 made up 16.5% of the total United States population, estimated to reach 85.7 million by 2050, accounting for 20% of the total United States Population.

Competitive Landscape

The major players operating in the global mantle cell lymphoma market are F. Hoffman La Roche Ltd, Abbvie, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, and Johnson and Johnson. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the mantle cell lymphoma market. For instance, on 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma. Also, on July 27, 2021, AbbVie and Calico announced the extension of collaboration focused on aging and age-related diseases.

Kite Pharma, Inc. (Gilead Sciences, Inc.)

Overview:

Kite Pharma is a branch of Gilead Sciences, Inc. Kite Pharma was established in 2009 with its headquarters in California, United States. Kite Pharma is a leading American biotechnology company involved in developing cancer immunotherapy products that are majorly focused on the genetically-engineered autologous T cell therapy with chimeric antigen receptors.

Product Portfolio:

The Kite Pharma, Inc. (Gilead Sciences, Inc.) product portfolio for mantle cell lymphoma contains Tecartus.

The global mantle cell lymphoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Increasing Prevalence of Cancer Cases
    • 4.1.2. Restraints
      • 4.1.2.1. The High Development Cost
      • 4.1.2.2. Side Effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment
    • 7.1.2. Market Attractiveness Index, By Therapy Type Segment
  • 7.2. Targeted Therapy
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chemotherapy
  • 7.4. Radiotherapy
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Injectable

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cancer Research Center
  • 9.4. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffman La Roche Ltd
  • 12.3. Abbvie, Inc.
  • 12.4. Celgene Corporation
  • 12.5. Eli Lilly and Company
  • 12.6. Amgen, Inc.
  • 12.7. Takeda Pharmaceutical Co. Ltd
  • 12.8. AstraZeneca Plc
  • 12.9. Johnson and Johnson

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us